Equity research consensus for Foghorn Therapeutics is categorized primarily as a strong buy, reflecting widespread institutional optimism regarding its proprietary chromatin-regulatory drug discovery engine. Analysts project significant percentage upside from current trading levels, driven by clinical milestones in oncology and targeted genetic therapies.